IP Library › Granted Patent US 12,252,707
Granted Patent B2
US 12,252,707 · App. 17/245,952 · Granted Mar 18, 2025

Delivery, Engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

Inventors: Feng Zhang (Cambridge, MA); Randall Jeffrey Platt (Cambridge, MA); Guoping Feng (Cambridge, MA); Yang Zhou (Cambridge, MA)
Assignees: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
C12N15/907A01K67/0275A01K67/0278C12N9/22C12N9/96C12N15/01C12N15/102C12N15/63C12N15/8213C12N15/85C12N15/8509C12N15/86C12N15/90A01K2217/05A01K2217/052A01K2217/07A01K2217/072A01K2227/105A01K2267/03C12N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,707
App. No.
17/245,952
Granted
Mar 18, 2025
Kind
B2
Abstract

The invention provides for delivery, engineering and optimization of systems, methods and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

Claims (14)

1. A non-human transgenic animal comprising an exogenous conditional expression cassette knocked into an endogenous genomic locus, wherein the conditional expression cassette comprises a nucleotide sequence encoding a Cas9 protein, wherein the expression of the Cas9 protein is dependent on and inducible by Cre recombinase, wherein the nucleotide sequence encoding the Cas9 protein further encodes a first nuclear localization signal (NLS) at the N-terminus of the Cas9 protein and a second NLS at the C-terminus of the Cas protein.

2. The non-human animal of claim 1 , which is a mouse, a rat, or a rabbit.

3. The non-human animal of claim 1 , wherein the conditional expression cassette is knocked into a Rosa26 locus.

4. The non-human animal of claim 1 , wherein the Cas9 is a Streptococcus pyogenes Cas9.

5. The non-human animal of claim 1 , wherein the expression cassette further comprises a promoter and a stop cassette element, wherein the stop cassette element is located downstream of the promoter and upstream of the nucleotide sequence encoding the Cas9 protein.

6. The non-human animal of claim 5 , wherein the stop cassette element is loxP-SV40 poly A x3-loxP.

7. The non-human animal of claim 5 , wherein the promoter is a pCAG promoter.

8. The non-human animal of claim 1 , wherein the expression cassette further comprises a nucleotide sequence encoding a peptide cleavage sequence.

9. The non-human animal of claim 1 , wherein the expression cassette further comprises a nucleotide sequence encoding an enhanced green fluorescent protein (EGFP).

10. The non-human animal of claim 1 , wherein the expression cassette further comprises a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE).

11. The non-human animal of claim 1 , wherein the expression cassette further comprises a bovine growth hormone poly-A signal sequence (bGHpolyA).

12. The non-human animal of claim 1 , wherein the expression cassette further comprises, downstream of the nucleotide sequence encoding the Cas9 protein, a nucleotide sequence encoding a peptide cleavage sequence, a nucleotide sequence encoding EGFP, a WPRE and a bGHpolyA.

13. A transgenic mouse comprising an exogenous conditional expression cassette knocked into a Rosa26 locus, wherein the conditional expression cassette comprises a nucleotide sequence encoding a Cas9 protein, wherein the expression of the Cas9 protein is dependent on and inducible by Cre recombinase, wherein the nucleotide sequence encoding the Cas9 protein further encodes a first nuclear localization signal (NLS) at the N-terminus of the Cas9 protein and a second NLS at the C-terminus of the Cas protein.

14. The transgenic mouse of claim 13 , wherein the expression cassette further comprises a pCAG promoter and a loxP-SV40 polyA x3-loxP stop cassette element, wherein the stop cassette element is located downstream of the promoter and upstream of the nucleotide sequence encoding the Cas9 protein; wherein the expression cassette further comprises, downstream of the nucleotide sequence encoding the Cas9 protein, a nucleotide sequence encoding a peptide cleavage sequence, a nucleotide sequence encoding EGFP, a WPRE and a bGHpolyA.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2024
From: ZHANG, FENG
To: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 068660/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2024
From: PLATT, RANDALL JEFFREY; FENG, GOUPING; ZHOU, YANG
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 068660/0882 →
Continuity (14)
Division 15349603 · Nov 11, 2016
Continuation 14481339 · Sep 9, 2014
Continuation PCTUS2013074667 · Dec 12, 2013
Provisional Application 61847537 · Jul 17, 2013
Provisional Application 61836123 · Jun 17, 2013
Provisional Application 61835931 · Jun 17, 2013
Provisional Application 61828130 · May 28, 2013
Provisional Application 61819803 · May 6, 2013
Provisional Application 61814263 · Apr 20, 2013
Provisional Application 61806375 · Mar 28, 2013
Provisional Application 61802174 · Mar 15, 2013
Provisional Application 61791409 · Mar 15, 2013
Provisional Application 61769046 · Feb 25, 2013
Related Publication 20210269831A1 · Sep 2, 2021
References Cited (400)
US 5622856A · Natsoulis · 1997 [cited by applicant]
US 6251677B1 · Wilson et al. · 2001 [cited by applicant]
US 7601492B2 · Fu et al. · 2009 [cited by applicant]
US 7691995B2 · Zamore et al. · 2010 [cited by applicant]
US 8697359B1 · Zhang · 2014 [cited by applicant]
US 8771945B1 · Zhang · 2014 [cited by applicant]
US 8865406B2 · Zhang et al. · 2014 [cited by applicant]
US 8871445B2 · Cong et al. · 2014 [cited by applicant]
US 8889418B2 · Zhang et al. · 2014 [cited by applicant]
US 8895308B1 · Zhang et al. · 2014 [cited by applicant]
US 8932814B2 · Cong et al. · 2015 [cited by applicant]
US 8945839B2 · Zhang · 2015 [cited by applicant]
US 8993233B2 · Zhang et al. · 2015 [cited by applicant]
US 9512446B1 · Joung et al. · 2016 [cited by applicant]
US 9549901B2 · Shi et al. · 2017 [cited by applicant]
US 9597357B2 · Gregory et al. · 2017 [cited by applicant]
US 9623071B2 · Guo et al. · 2017 [cited by applicant]
US 9637739B2 · Siksnys et al. · 2017 [cited by applicant]
US 9701964B2 · Clube et al. · 2017 [cited by applicant]
US 9738908B2 · Wu · 2017 [cited by applicant]
US 9834791B2 · Zhang et al. · 2017 [cited by applicant]
US 9873894B2 · Conway et al. · 2018 [cited by applicant]
US 9926546B2 · Joung et al. · 2018 [cited by applicant]
US 10047355B2 · Yin · 2018 [cited by applicant]
US 10190137B2 · Zhang et al. · 2019 [cited by applicant]
US 10301651B2 · Doudna et al. · 2019 [cited by applicant]
US 10494621B2 · Zhang et al. · 2019 [cited by applicant]
US 10583203B2 · De Fougerolles et al. · 2020 [cited by applicant]
US 10640788B2 · Zhang et al. · 2020 [cited by applicant]
US 10660943B2 · Bikard et al. · 2020 [cited by applicant]
US 10669557B2 · Guschin et al. · 2020 [cited by applicant]
US 10767194B2 · Church et al. · 2020 [cited by applicant]
US 10781444B2 · Zhang et al. · 2020 [cited by applicant]
US 10851357B2 · Davidson et al. · 2020 [cited by applicant]
US 10930367B2 · Zhang et al. · 2021 [cited by applicant]
US 11041173B2 · Zhang · 2021 [cited by examiner]
US 11116729B2 · Dahlman · 2021 [cited by applicant]
US 11124796B2 · Sharp · 2021 [cited by examiner]
US 11559588B2 · Lundberg et al. · 2023 [cited by applicant]
US 11578312B2 · Zhang et al. · 2023 [cited by applicant]
US 11597949B2 · Zhang et al. · 2023 [cited by applicant]
US 20030186238A1 · Allawi et al. · 2003 [cited by applicant]
US 20040111221A1 · Beattie et al. · 2004 [cited by applicant]
US 20050196851A1 · Uckun · 2005 [cited by applicant]
US 20050220796A1 · Dynan et al. · 2005 [cited by applicant]
US 20060178297A1 · Troy et al. · 2006 [cited by applicant]
US 20060234247A1 · Puttaraju et al. · 2006 [cited by applicant]
US 20070016012A1 · Hartlep et al. · 2007 [cited by applicant]
US 20070244031A1 · Lu et al. · 2007 [cited by applicant]
US 20080293655A1 · Aygun et al. · 2008 [cited by applicant]
US 20090215169A1 · Wandless et al. · 2009 [cited by applicant]
US 20100055798A1 · Battersby · 2010 [cited by applicant]
US 20100076057A1 · Sontheimer et al. · 2010 [cited by applicant]
US 20100081707A1 · Ali et al. · 2010 [cited by applicant]
US 20100093617A1 · Barrangou et al. · 2010 [cited by applicant]
US 20100233084A1 · Narasimhaswamy et al. · 2010 [cited by applicant]
US 20110016540A1 · Weinstein et al. · 2011 [cited by applicant]
US 20110059502A1 · Chalasani · 2011 [cited by applicant]
US 20110189776A1 · Terns et al. · 2011 [cited by applicant]
US 20110223638A1 · Wiedenheft et al. · 2011 [cited by applicant]
US 20110239315A1 · Bonas et al. · 2011 [cited by applicant]
US 20120029891A1 · Behlke et al. · 2012 [cited by applicant]
US 20130096182A1 · Chatterjee et al. · 2013 [cited by applicant]
US 20130130248A1 · Haurwitz et al. · 2013 [cited by applicant]
US 20130315831A1 · Shi et al. · 2013 [cited by applicant]
US 20140068797A1 · Doudna et al. · 2014 [cited by applicant]
US 20140294771A1 · Schaffer et al. · 2014 [cited by applicant]
US 20140295557A1 · Joung et al. · 2014 [cited by applicant]
US 20140315985A1 · May et al. · 2014 [cited by applicant]
US 20140342456A1 · Mali et al. · 2014 [cited by applicant]
US 20140356956A1 · Church et al. · 2014 [cited by applicant]
US 20140357530A1 · Zhang et al. · 2014 [cited by applicant]
US 20150045546A1 · Siksnys et al. · 2015 [cited by applicant]
US 20150071899A1 · Liu et al. · 2015 [cited by applicant]
US 20150071903A1 · Liu et al. · 2015 [cited by applicant]
US 20150071906A1 · Liu et al. · 2015 [cited by applicant]
US 20150232881A1 · Glucksmann et al. · 2015 [cited by applicant]
US 20150247150A1 · Zhang et al. · 2015 [cited by applicant]
US 20150291965A1 · Zhang et al. · 2015 [cited by applicant]
US 20150322457A1 · Kim et al. · 2015 [cited by applicant]
US 20150353905A1 · Weiss et al. · 2015 [cited by applicant]
US 20160017366A1 · Chen et al. · 2016 [cited by applicant]
US 20160024510A1 · Bikard et al. · 2016 [cited by applicant]
US 20160024524A1 · Joung et al. · 2016 [cited by applicant]
US 20160130609A1 · Doudna et al. · 2016 [cited by applicant]
US 20160237456A1 · Church et al. · 2016 [cited by applicant]
US 20160251648A1 · Wang et al. · 2016 [cited by applicant]
US 20160281072A1 · Zhang · 2016 [cited by applicant]
US 20160298135A1 · Chen et al. · 2016 [cited by applicant]
US 20160298137A1 · Chen et al. · 2016 [cited by applicant]
US 20160312199A1 · Joung et al. · 2016 [cited by applicant]
US 20160324938A1 · Bikard et al. · 2016 [cited by applicant]
US 20160340662A1 · Zhang et al. · 2016 [cited by applicant]
US 20170175144A1 · Zhang et al. · 2017 [cited by applicant]
US 20170191082A1 · Chen et al. · 2017 [cited by applicant]
US 20170327806A1 · Joung et al. · 2017 [cited by applicant]
US 20180127783A1 · Zhang et al. · 2018 [cited by applicant]
US 20180230495A1 · Doudna et al. · 2018 [cited by applicant]
US 20190010471A1 · Zhang et al. · 2019 [cited by applicant]
US 20200282026A1 · Bikard et al. · 2020 [cited by applicant]
US 20200282027A1 · Bikard et al. · 2020 [cited by applicant]
US 20210060140A1 · Bikard et al. · 2021 [cited by applicant]
US 20210060141A1 · Bikard et al. · 2021 [cited by applicant]
US 20220273566A1 · Dahlman · 2022 [cited by applicant]
BR 112015013784 · 2017 [cited by applicant]
CA 2619833A1 · 2007 [cited by applicant]
CN 101228176 · 2008 [cited by applicant]
CN 103343120 · 2013 [cited by applicant]
CN 103388006 · 2013 [cited by applicant]
CN 103668472 · 2014 [cited by applicant]
CN 104520429A · 2015 [cited by applicant]
CN 104854241A · 2015 [cited by applicant]
CN 107532161A · 2018 [cited by applicant]
EP 2591770A2 · 2013 [cited by applicant]
EP 2784162 · 2014 [cited by applicant]
EP 2764103 · 2014 [cited by applicant]
EP 2771468 · 2014 [cited by applicant]
EP 2828386A1 · 2015 [cited by applicant]
FR 2872170A1 · 2005 [cited by applicant]
IN 492015 · 2015 [cited by applicant]
JP 2004519245A · 2004 [cited by applicant]
JP 2004537285A · 2004 [cited by applicant]
JP 2005509409A · 2005 [cited by applicant]
JP 2006513694A · 2006 [cited by applicant]
JP 2006518996A · 2006 [cited by applicant]
JP 2007501626A · 2007 [cited by applicant]
JP 2009502170A · 2009 [cited by applicant]
JP 2009536827A · 2009 [cited by applicant]
JP 2010507680A · 2010 [cited by applicant]
JP 2010522547A · 2010 [cited by applicant]
JP 2012506254A · 2012 [cited by applicant]
JP 2012508235 · 2012 [cited by applicant]
JP 2012510812A · 2012 [cited by applicant]
JP 2012511332A · 2012 [cited by applicant]
JP 2012523234A · 2012 [cited by applicant]
JP 2012529287A · 2012 [cited by applicant]
JP 2013500045A · 2013 [cited by applicant]
JP 2013513389A · 2013 [cited by applicant]
JP 2013518602A · 2013 [cited by applicant]
JP 2013544077A · 2013 [cited by applicant]
JP 2014526279A · 2014 [cited by applicant]
JP 2015523856A · 2015 [cited by applicant]
JP 2016500003A · 2016 [cited by applicant]
JP 2016500262A · 2016 [cited by applicant]
JP 2016501531 · 2016 [cited by applicant]
JP 2016501532A · 2016 [cited by applicant]
JP 2016025710A · 2016 [cited by applicant]
JP 2016502840A · 2016 [cited by applicant]
JP 2016504026A · 2016 [cited by applicant]
JP 2016505256A · 2016 [cited by applicant]
JP 2016093196 · 2016 [cited by applicant]
JP 2016516169A · 2016 [cited by applicant]
JP 2016517954A · 2016 [cited by applicant]
JP 2016131404A · 2016 [cited by applicant]
JP 2016520317A · 2016 [cited by applicant]
JP 2016521554A · 2016 [cited by applicant]
JP 2016521975A · 2016 [cited by applicant]
JP 2016521995 · 2016 [cited by applicant]
JP 2016523082A · 2016 [cited by applicant]
JP 2016524472 · 2016 [cited by applicant]
JP 2016182140A · 2016 [cited by applicant]
JP 2017501151A · 2017 [cited by applicant]
JP 2017501699 · 2017 [cited by applicant]
JP 6395765 · 2018 [cited by applicant]
RU 2009136452A · 2011 [cited by applicant]
WO WO02074968A1 · 2002 [cited by applicant]
WO WO02080851A2 · 2002 [cited by applicant]
WO WO03014318A2 · 2003 [cited by applicant]
WO WO03104414A2 · 2003 [cited by applicant]
WO WO2004029219A2 · 2004 [cited by applicant]
WO WO2004046321A2 · 2004 [cited by applicant]
WO WO2004062618A2 · 2004 [cited by applicant]
WO WO2005014791 · 2005 [cited by applicant]
WO WO2005049642A2 · 2005 [cited by applicant]
WO WO2007014275A2 · 2007 [cited by applicant]
WO WO2007134161A2 · 2007 [cited by applicant]
WO WO2008093152A1 · 2008 [cited by applicant]
WO WO2008108989 · 2008 [cited by applicant]
WO WO2008116860A2 · 2008 [cited by applicant]
WO WO2008147438A2 · 2008 [cited by applicant]
WO WO2010011961A2 · 2010 [cited by applicant]
WO WO2010048228A2 · 2010 [cited by applicant]
WO WO2010054108 · 2010 [cited by applicant]
WO WO2010065123A1 · 2010 [cited by applicant]
WO WO2010068816A1 · 2010 [cited by applicant]
WO WO2010075424A2 · 2010 [cited by applicant]
WO WO2010079430A1 · 2010 [cited by applicant]
WO WO2010118077A1 · 2010 [cited by applicant]
WO WO2010143917 · 2010 [cited by applicant]
WO WO2011011767A1 · 2011 [cited by applicant]
WO WO2011016840A2 · 2011 [cited by applicant]
WO WO2011036510A1 · 2011 [cited by applicant]
WO WO2011064736A1 · 2011 [cited by applicant]
WO WO2011072246A2 · 2011 [cited by applicant]
WO WO2011076873A1 · 2011 [cited by applicant]
WO WO2011100058A1 · 2011 [cited by applicant]
WO WO2011146121A1 · 2011 [cited by applicant]
WO WO2012012738A1 · 2012 [cited by applicant]
WO WO2012031205 · 2012 [cited by applicant]
WO WO2012051343A1 · 2012 [cited by applicant]
WO WO2012149470A1 · 2012 [cited by applicant]
WO WO2012164565A1 · 2012 [cited by applicant]
WO WO2013044008A2 · 2013 [cited by applicant]
WO WO2013052681 · 2013 [cited by applicant]
WO WO20135052681A1 · 2013 [cited by applicant]
WO WO2013071440A1 · 2013 [cited by applicant]
WO WO2013078400A1 · 2013 [cited by applicant]
WO WO2013082519A2 · 2013 [cited by applicant]
WO WO2013098244 · 2013 [cited by applicant]
WO WO2013130824A1 · 2013 [cited by applicant]
WO WO2013141680A1 · 2013 [cited by applicant]
WO WO2013142578A1 · 2013 [cited by applicant]
WO WO2013155572 · 2013 [cited by applicant]
WO WO2013176772A1 · 2013 [cited by applicant]
WO WO2014165349A1 · 2014 [cited by applicant]
WO WO2014065596A1 · 2014 [cited by applicant]
WO WO2014089290A1 · 2014 [cited by applicant]
WO WO2014093479 · 2014 [cited by applicant]
WO WO2014093595 · 2014 [cited by applicant]
WO WO2014093622A2 · 2014 [cited by applicant]
WO WO2014093635A1 · 2014 [cited by applicant]
WO WO2014093655 · 2014 [cited by applicant]
WO WO2014093661 · 2014 [cited by applicant]
WO WO2014093694A1 · 2014 [cited by applicant]
WO WO2014093701A1 · 2014 [cited by applicant]
WO WO2014093709 · 2014 [cited by applicant]
WO WO2014093712A1 · 2014 [cited by applicant]
WO WO2014093718 · 2014 [cited by applicant]
WO WO2014099744 · 2014 [cited by applicant]
WO WO2014099750A2 · 2014 [cited by applicant]
WO WO2015031775 · 2014 [cited by applicant]
WO WO2014144761A2 · 2014 [cited by applicant]
WO WO2014165825A2 · 2014 [cited by applicant]
WO WO2014186585A2 · 2014 [cited by applicant]
WO WO2014191518A1 · 2014 [cited by applicant]
WO WO2014197568A2 · 2014 [cited by applicant]
WO WO2014197748A2 · 2014 [cited by applicant]
WO WO2014204724A1 · 2014 [cited by applicant]
WO WO2014204725 · 2014 [cited by applicant]
WO WO2014204726A1 · 2014 [cited by applicant]
WO WO2014204727A1 · 2014 [cited by applicant]
WO WO2014204728 · 2014 [cited by applicant]
WO WO2014204729A1 · 2014 [cited by applicant]
WO WO2015006747A2 · 2015 [cited by applicant]
WO WO2015035136A2 · 2015 [cited by applicant]
WO WO2015048577 · 2015 [cited by applicant]
WO WO2015048690 · 2015 [cited by applicant]
WO WO2015065964A1 · 2015 [cited by applicant]
WO WO2015070083A1 · 2015 [cited by applicant]
WO WO2015071474A2 · 2015 [cited by applicant]
WO WO2015089351A1 · 2015 [cited by applicant]
WO WO2015089364A1 · 2015 [cited by applicant]
WO WO2015089419A2 · 2015 [cited by applicant]
WO WO2015089427A1 · 2015 [cited by applicant]
WO WO2015113063A1 · 2015 [cited by applicant]
WO WO2016022866A1 · 2016 [cited by applicant]
WO WO2016073955A2 · 2016 [cited by applicant]
WO WO2016141224A1 · 2016 [cited by applicant]
Bauer et al., “Fine-Mapping and Genome Editing Reveal an Essential Erythroid Enhancer at the HbF-Associated BCL11A Locus,” Blood, Nov. 15, 2013, vol. 122, No. 21 (3 pages). [cited by applicant]
Koller et al., “Inactivating the beta2-microglobulin locus in mouse embryonic stem cells by homologous recombination,” Proceedings of the National Academy of Sciences, USA, Nov. 1989, vol. 86 (pp. 8932-8935). [cited by applicant]
Li et al., “Genetic correction using engineered nucleases for gene therapy applications,” The Japanese Society of Developmental Biologists; Development, Growth & Differentiation, 2014, vol. 56 (pp. 63-77). [cited by applicant]
Louwen et al., “The Role of CRISPR-Cas Systems in Virulence of Pathogenic Bacteria,” Microbiology and Molecular Biology Reviews, Mar. 2014, vol. 78, No. 1 (pp. 74-88). [cited by applicant]
Reik et al., “Targeted Gene Modification in Hematopoietic Stem Cells: A Potential Treatment for Thalassemia and Sickle Cell Anemia,” Blood, American Society of Hematology, Nov. 1, 2013, vol. 122, No. 21 (p. 434). [cited by applicant]
Singleton, “Exome sequencing: a transformative technology,” The Lancet/neurology, Oct. 2011, vol. 10 (pp. 942-946). [cited by applicant]
Xu et al., “Identification of BCL 11 A Structure Function Domains for Fetal Hemoglobin Silencing,” Blood, Nov. 15, 2013, vol. 122, No. 21 (4 pages). [cited by applicant]
Love et al., “Lipid-like materials for low-dose, in vivo gene silencing,” Proceedings of the National Academy of Sciences, Feb. 2, 2010, vol. 107, No. 5 (pp. 1864-1869). [cited by applicant]
Semple et al., “Rational design of cationic lipids for siRNA delivery,” Nature Biotechnology, Feb. 2010, vol. 28, No. 2 (pp. 172-178). [cited by applicant]
David et al., “Non-viral nanosystems for systemic siRNA delivery,” Pharmacological Research, 2010, vol. 62 (pp. 100-114). [cited by applicant]
Gjetting et al., “In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection,” International Journal of Nanomedicine, 2010, vol. 5 (pp. 371-383). [cited by applicant]
Hwang et al., “Efficient genome editing in zebrafish using a CRISPR-Cas system,” Nature Biotechnology, Jan. 1, 2013, vol. 31, No. 3, Supplementary Materials (pp. 1-21). [cited by applicant]
Guilinger et al., “Fusion of catalytically inactive Cas9 to Fokl nuclease improves the specificity of genome modification,” Nature Biotechnology, vol. 32, No. 6, Jun. 2014 (pp. 577-582). [cited by applicant]
Slaymaker et al., “Rationally engineered Cas9 nucleases with improved specificity”, Science, vol. 351, No. 6268, Jan. 1, 2016, pp. 84-88. [cited by applicant]
Taylor, G., “Introduction to phasing,” Acta Crystallographica Section D Biological Crystallography, 2010, D66 (pp. 325-338). [cited by applicant]
“Crispr Genome Engineering Resources” XP055167591, Oct. 5, 2013, https://web.archive.org/web/2013100500 [retrieved on Feb. 5, 2015]. [cited by applicant]
“Fixes, extra genomes, and improvements to the CRISPR Design Tool” Google Groups, XP055167583, Oct. 21, 2013, URL:https://groups.google.com/forum/#!topic/crispr/g9Q8U1tNSis [retrieved on Feb. 5, 2015]. [cited by applicant]
“The CRISPR Revolution,” Catalyst Magazine, College of Chemistry, University of California, Berkeley, http://catalyst.berkeley.edu/slideshow/the-crispr-revolution/[Dec. 19, 2014 12:40:53] (Jul. 9, 2014). [cited by applicant]
A. Amsterdam et al., “Identification of 315 genes essential for early zebrafish development,” proc Natl Acad Sci., vol. 101, Aug. 31, 2004, pp. 12792-12797, 6 pages. [cited by applicant]
A. Fire et al., “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans,” Nature, vol. 391, Feb. 19, 1998, pp. 806-811, 6 pages. [cited by applicant]
A. Subramanian et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proc Natl Acad Sci., vol. 102, Oct. 25, 2005, pp. 15545-15550, 6 pages. [cited by applicant]
A.C. Spradling et al., “The Berkeley [cited by applicant]
A.H. Tong et al., “Global mapping of the yeast genetic interaction network,” Science, vol. 303, Feb. 6, 2004, pp. 808-813, 6 pages. [cited by applicant]
A.L. Lin and D.H Gutmann, “Advances in the treatment of neurofibromatosis-associated tumours,” Nature, vol. 10, Nov. 2013, pp. 616-624, 9 pages. [cited by applicant]
A.P. Blanchard and L. Hood, “Sequence to array: probing the genome's secrets,” Nat Biotechnol, vol. 14, Dec. 14, 1996, p. 1649. [cited by applicant]
Abudayyeh, et al., “C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector,” Science, vol. 10, Jun. 2, 2016, pp. 1-16, 18 pages. [cited by applicant]
Addgene Materials, “CRISPR/cas Plasmids and Resources”, downloaded from https://www.addgene.org/crispr/, May 6, 2015, 3 pages. [cited by applicant]
Addgene Materials, “Engineering with Addgene's Help”, Addgene Newsletter, Mar. 2013, downloaded from https://archive.constantcontact.com/fs126/1103481513180/archive/1112756362265.html, Oct. 14, 2014, 4 pages. [cited by applicant]
Addgene Reagent distribution list for Zhang Lab with Plasmid Name, date unknown (prior to May 10, 2015), 2 pages. [cited by applicant]
Addgene, “gRNA_Cloning Vector”, retrieved on Jan. 30, 2019, <https://www/addgenen.org/41824/> 2 pages. [cited by applicant]
Al-Attar, et al., “Clustered regularly interspaced short palindromic repeats (CRISPRs): the hallmark of an ingenious antiviral defense mechanism in prokaryotes” Biol Chem., vol. 392, No. 4, Apr. 2011, pp. 277-289, 13 pa… [cited by applicant]
Alberts, et al., “Intracellular Compartments and Protein Sorting,” Garland Science, 4 ed., 2002, pp. 671-676, 8 pages. [cited by applicant]
Allen, et al., “Liposomal drug delivery systems: From concept to clinical applications” Advanced Drug Delivery Reviews, vol. 65, 2013, pp. 36-48, 13 pages. [cited by applicant]
Andreas, et al., “Enhanced efficiency through nuclear localization signal fusion on phage C31-integrase: activity comparison with Cre and FLPe recombinase in mammalian cells”, Nucleic Acids Research, Apr. 15, 2002, vol.… [cited by applicant]
Anguela et al., “Robust ZFN-mediated geno1ne editing in adult hemophilic mice”, Blood, vol. 122, No. 19, Nov. 7, 2013, (pp. 3283-3287). [cited by applicant]
[cited by applicant]
Asuri, P., et al., “Directed Evolution of Adeno-Associated Virus for Enhanced Gene Delivery and Gene Targeting in Human Pluripotent Stem Cells,” Molecular Therapy, vol. 30, 2012, No. pp. 329-338, 10 pages. [cited by applicant]
Au, et al., “Characterization of a baculovirus nuclear localization signal domain in the late express factor 3 protein”, Virology, vol. 385, 2009, pp. 209-217. [cited by applicant]
Ausubel, et al. “Compendium of Methods from Current Protocols in Molecular Biology”, Short Protocols in Molecular Biology, 4 ed., 1999, 9-0, 9-4, 5 pages. [cited by applicant]
Autofluorescence MIT Flow Cytometry Core Facility (2018), 6 pages. [cited by applicant]
B. Langmead et al., “Ultrafast and memory-efficient alignment of short DNA sequences to the human genome,” Genome biology, vol. 10, Mar. 4, 2009, 10 pages. [cited by applicant]
B.Langmead and S.L. Salzberg, “Fast gapped-read alignment with Bowtie 2,” Nat Meth, vol. 9, 2012, pp. 357-359, 3 pages. [cited by applicant]
B.Scappini et al., “Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein,” Cancer, vol. 100, Apr. 1, 2004, pp. 1459-1471, 13 pages. [cited by applicant]
B.Sonnichsen et al., “Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans,” Nature, vol. 434, Mar. 24, 2005, pp. 462-469, 8 pages. [cited by applicant]
Bae, T. and Schneewind, O. “Allelic replacement in [cited by applicant]
Baena-Lopez, L., et al., “Accelerated homologous recombination and subsequent genome modification in [cited by applicant]
Baiker, et al. “The Immediate-Early 63 Protein of Varicella-Zoster Virus: Analysis of Functional Domains Required for Replication In Vitro and for T-Cell and Skin Tropism in the SCIDhu Model In Vivo”, Journal of Virolog… [cited by applicant]
Baker, M., “Gene editing at CRISPR Speed,” Nature Biotechnology, vol. 32, 2014, pp. 309-312, 4 pages. [cited by applicant]
Balboa, et al., “Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation. (plus Supplemental Information)”, Stem Cell Reports, vol. 5, Sep. 8, 2015, pp. 4… [cited by applicant]
Banaszewska, A., et al., “Proprotein Convertase Subtilisin/Kexin Type 9: A New Target Molecule For Gene Therapy,” Cellular & Molecular Biology Letters, vol. 17, 2012, pp. 228-239, 12 pages. [cited by applicant]
Barrangou and Van Der Oost (Eds.), “CRISPR-Cas Systems,” Springer Heidelberg, 2013, pp. i-299. [cited by applicant]
Barrangou, R. et al., “CRISPR provides acquired resistance against viruses in prokaryotes,” Science, vol. 315, Mar. 23, 2007, pp. 1709-1712, 6 pages. [cited by applicant]
Barrangou, R., “RNA-mediated programmable DNA cleavage,” Nature Biotechnology, vol. 30, 2012, pp. 836-388, 13 pages. [cited by applicant]
Bassett, et al. “Highly Efficient Targeted Mutagenesis of [cited by applicant]
Bassett, et al., “A Genome-Wide CRISPR Library for High-Throughput Genetic Screening in [cited by applicant]
Bauer, et al., “An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level,” Science, vol. 342, Oct. 11, 2013, pp. 253-257, 4 pages. [cited by applicant]
Beerli, et al. “Positive and negative regulation of endogenous genes by designed transcription factors” PNAS, vol. 97, Feb. 15, 2000, pp. 1495-1500. [cited by applicant]
Beerli, et al., “Toward controlling gene expression at will: Specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks”, Proc. Natl. Acad. Sci., v… [cited by applicant]
Beerli, R., et al., “Engineering polydactyl zinc-finger transcription factors,” Nature Biotechnology, vol. 20, Feb. 2002, pp. 135-141. [cited by applicant]
Bennett, et al., “Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina”, Proc. Natl. Acad. Sci., vol. 96, Aug. 1999, pp. 9920-9925. [cited by applicant]
Bergemann, et al., Excision of specific DNA-sequences from integrated retroviral vectors via site-specific recombination:, Nucleic Acids Res., vol. 23, Oct. 2, 1995, pp. 4451-4456. [cited by applicant]
Berns, K., et al., “A Large-Scale RNAi Screen in Human Cells Identifies New Components of the p53 Pathway,” Nature, vol. 428, Mar. 25, 2004, pp. 431-437. [cited by applicant]
Bhaya, D., et al., “CRISPR-Cas Systems in Bacteria and Archaea: Versatile Small RNAs for Adaptive Defense and Regulation,” Annual Review of Genetics, vol. 45, 2011, pp. 273-297, (27 pages). [cited by applicant]
Bikard et al., “Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials”, Nature Biotechnology, vol. 32, No. 11, Nov. 2014 (pp. 1146-1151). [cited by applicant]
Bikard, et al. “CRISPR Interference Can Prevent Natural Transformation And Virulence Acquisition During In Vivo Bacterial Infection,” Cell Host & Microbe, vol. 12, 2012, pp. 177-186. [cited by applicant]
Bikard, et al., Supplementary Information for: “CRISPR Interference Can Prevent Natural Transformation And Virulence Acquisition During In Vivo Bacterial Infection,” Cell Host & Microbe, vol. 12, 2012, pp. 177-186. [cited by applicant]
Birch, et al., “Plant Transformation: Problems and Strategies for Practical Application”, Annu. Rev. Plant Physiol. Plant Mol. Biol., vol. 48, 1997, pp. 297-326. [cited by applicant]
Bloom, et al., “Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases”, Molecular Therapy, vol. 21, Oct. 2013, pp. 1889-1897. [cited by applicant]
Bobis-Wozowicz, S., et al., “Targeted genome editing in pluripotent stem cells using zinc-finger nucleases,” Methods, vol. 53, 2012, pp. 339-346. [cited by applicant]
Boch, et al., “Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors,” Science, vol. 326, Dec. 11, 2009, pp. 1509-1512. [cited by applicant]
Boch, et al., “Xanthomonas AvrBs3 Family-Type III Effectors: Discovery And Function”, Annu. Rev. Phytopathol, vol. 48, 2010, pp. 419-436 (21 pages). [cited by applicant]
Boden, et al., “Efficient Gene Transfer of HIV-1-Specific Short Hairpin RNA into Human Lymphocytic Cells Using Recombinant Adeno-associated Virus Vectors”, Molecular Therapy, vol. 9, 2004, pp. 396-402. [cited by applicant]
Bogdanove, et al., “TAL Effectors: Customizable Proteins for DNA Targeting”, Science, vol. 333, 2011, pp. 1843-1846. [cited by applicant]
Bohm et al., “The computer program LUDI: A new method for the de novo design of enzyme inhibitors”, Journal of Computer-Aided Molecular Design, vol. 6, 1992, pp. 61-78. [cited by applicant]
Botta, S. et al., “Transcriptional Repression with Zinc-Finger and Tale Protein Scaffold”, Molecular Therapy, 2013, Supplement 1, p. S208, Abstract No. 539. [cited by applicant]
Bouard, et al., “Themed Section: Vector Design and Drug Delivery Review, Viral vectors: from virology to transgene expression”, British Journal of Pharmacology, vol. 157, 2009, pp. 153-165. [cited by applicant]
Boutros, et al., “Genome-wide RNAi analysis of growth and viability in Drosophila cells,” Science, American Association for the Advancement of Science, vol. 303, Feb. 6, 2004, pp. 832-835. [cited by applicant]
Branden, C., and Tooze, J., “Prediction, Engineering, and Design of Protein Structures: Introduction to Protein Structure,” Garland Publishing, Inc., Chapter 16, 1991, p. 247. [cited by applicant]
Briner, et al., “Guide RNA Functional Modules Direct Cas9 Activity and Orthogonality”, Molecular Cell, vol. 56, 2014, pp. 333-339. [cited by applicant]
Brouns, S., “A Swiss Army Knife of Immunity,” Science, vol. 337, 2012, pp. 808-809. [cited by applicant]
Brouns, S., et al., “Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes,” Science, vol. 321, Aug. 15, 2008, pp. 960-964. [cited by applicant]
Brummelkamp Tr et al., “A system for stable expression of short interfering RNAs in mammalian cells,” Science, vol. 296, Apr. 19, 2002, pp. 550-553. [cited by applicant]
C. Cayrol et al., “The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes,” Blood, vol. 109, 2007, pp. 584-594. [cited by applicant]
C. Trapnell et al., “Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks,” Nature protocols, vol. 7, 2012, p. 562. [cited by applicant]
C. Trapnell et al., “TopHat: discovering splice junctions with RNA-Seq.,” Bioinformatics, vol. 25, 2009, pp. 1105-1111. [cited by applicant]
C.J, Echeverri et al., “Minimizing the risk of reporting false positives in large-scale RNAi screens,” Nature methods, vol. 3, Oct. 2006, p. 777. [cited by applicant]
C.M Johannessen et al., “COT drives resistance to RAF inhibition through MAP kinase pathway reactivation,” Nature, vol. 468, Dec. 16, 2010, p. 968. [cited by applicant]
C.M. Johnston et al., “Large-scale population study of human cell lines indicate that dosage compensation is virtually complete,” PLoS Genet., vol. 4, Jan. 2008, pp. 88-98, 11 pages. [cited by applicant]
Campeau, et al., “A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells”, PLoS One, vol. 4, 2009, pp. 1-17. [cited by applicant]
Canver, et al., “BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis,” Nature, vol. 527, 2015, pp. 192-197, including Supplementary Material. [cited by applicant]
Carr, et al., “Genome Engineering”, Nature Biotechnology, vol. 27, No. 12, Dec. 2009, pp. 1151-1162. [cited by applicant]
Carroll, D., “A CRISPR Approach to Gene Targeting,” Molecular Therapy, vol. 20, 2012, pp. 1658-1660. [cited by applicant]
Carroll., “Genome Engineering With Zing-Finger Nucleases”, Genetics, vol. 188, 2011, pp. 773-782. [cited by applicant]
Carroll., “Progress and prospects: Zinc-finger nucleases as gene therapy agents”, Gene Therapy, vol. 15, 2008, pp. 1463-1468. [cited by applicant]
Carte, J., et al., “Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes,” Genes Dev., vol. 22, 2008, pp. 3489-3496. [cited by applicant]
Cermak, T., et al., “Efficient Design and Assembly of Custom TALEN and Other TAL Effector-Based Constructs For DNA Targeting,” Nucleic Acids Research, vol. 39, No. 12, Apr. 14, 2011, pp. 1-11. [cited by applicant]
Chadderton, N., et al., “Improved Retinal Function in a Mouse Model of Dominant Retinitis Pigmentosa Following AAV-delivered Gene Therapy”, Molecular Therapy, vol. 17, Apr. 2009, pp. 593-599. [cited by applicant]
Chan, et al. “Characterization of the Kinetochore Binding Domain of CENP-E Reveals Interactions with the Kinetochore Proteins CENP-F and hBuBR1”, The Journal of Cell Biology, vol. 143, 1998, pp. 49-63. [cited by applicant]
Chan, Wai-Ting, et al., “Toxin-Antitoxin Genes of the Gram-Positive Pathogen [cited by applicant]
Chang, N., et al. “Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos”, Cell Research, vol. 23, 2013, pp. 465-472. [cited by applicant]
Chapdelaine et al., “Meganucleases can restore the reading frame of a mutated dystrophin”, Gene Therapy, vol. 17, 2010 (pp. 846-858). [cited by applicant]
Chen, Fuqiang, et al., “High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases”. Nature Methods, 2011, vol. 8, pp. 753-755, including Supplemental Online Methods. [cited by applicant]
Chen, Jieliang, et al., “An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases”, Molecular Therapy, vol. 22, 2014, pp. 303-311. [cited by applicant]
Chen, S., et al., “Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis”, Cell, vol. 160, 2015, pp. 1-15, http://dx.doi.org/10.1016/j.cell.2015.02.038. [cited by applicant]
Chevalier et al., “Homing endonuclease: structural and functional insight into the catalysts of intron/intein mobility,” Oxford University Press., vol. 29, 2001, pp. 3757-3774. [cited by applicant]
Chinnasamy, D., et al., “Multicistronic lentiviral vectors containing the FMCV 2A Cleavage factor demonstrate robust expression of encoded genes at limiting MOI,” Virology Journal, vol. 3, 2006, pp. 1-16. [cited by applicant]
Chiu, et al., “Engineered GFP as a vital reporter in plants”, Current Biology, vol. 6, 1996, pp. 325-330. [cited by applicant]
Cho, A., et al., “Generation of Transgenic Mice,” Current Protocols in Cell Biology, Chapter Unit 19.11, 2009, pp. 1-29. [cited by applicant]
Cho, Minseon, et al., “Quantitative selection and parallel characterization of aptamers,” PNAS, vol. 110, Nov. 12, 2013, pp. 18460-18465. [cited by applicant]
Cho, Seung Woo, et al. “Analysis off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases” Genome Research, vol. 24, 2014, pp. 132-141. [cited by applicant]
Cho, Seung Woo, et al., “Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease,” Nature Biotechnology, vol. 31 pp. 230-232, including Supplementary Information, 14 pages. [cited by applicant]
Chou, JY, and Mansfield, BC., “Recombinant AAV-directed gene therapy for type I glycogen storage diseases,” Expert Opinion on Biological Therapy, vol. 11, Aug. 2011, pp. 1011-1024. [cited by applicant]
Choulika, et al., “Transfer of Single Gene-Containing Long Terminal Repeats into the Genome of Mammalian Cells by a Retroviral Vector Carrying the cre Gene and the IoxP site”, Journal of Virology, vol. 70, 1996, pp. 179… [cited by applicant]
Christian, et al., “Supporting Information-Targeting DNA Double-Strand Breaks With TAL Effector Nucleases”, Genetics, 2010, pp. 1-8, DOI: 10.1534/110.120717:1SI-8SI. [cited by applicant]
Christian, et al., “Targeting DNA Double-Strand Breaks With TAL Effector Nucleases”, Genetics, vol. 186, Oct. 2010, pp. 757-761. [cited by applicant]
Chylinski, et al., “Classification and evolution of type II CRISPR-Cas systems”, Nucleic Acids Research, vol. 42, 2014, pp. 6091-6105, doi:10.1093Inarlgku241. [cited by applicant]
Chylinski, K., et al., “The tracrRNA and Cas9 Families of Type II CRISPR-Cas Immunity Systems,” RNA Biology, vol. 10, 2013, pp. 726-737. [cited by applicant]
Clark, K., et al., “A Tale of Two Nucleases: Gene Targeting for the Masses?” Zebrafish, vol. 8, No. 3, 2011, pp. 147-149. [cited by applicant]
Cockrell, “Berkeley's Wikipedian-in-residence is a first,” NewsCenter, Feb. 25, 2014, downloaded from https://newscenter.berkeley.edu/2014/02/25/berkeleys-wikipedian-in-residence-is-a-first/, May 8, 2015, 3 pages. [cited by applicant]
Community Corner, “CRISPR technology for gene therapy,” Nature Medicine, vol. 20, May 2014, pp. 476-477. [cited by applicant]
Cong, et al., Oct. 5, 2012 Manuscript including Supplementary Materials, “CRISPR-Assisted Mammalian Genome Engineering,” published as “Multiplex Genome Engineering Using CRISPR-Cas Systems,” Science, vol. 339, 2013, pp.… [cited by applicant]
Cong, L., et al., “Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains,” Nature Communications, vol. 3, Jul. 24, 2012, pp. 968-973. [cited by applicant]
Cong, L., et al., “In Vivo Genome Engineering With AAV Vector Carrying CRISPR-Cas9 System,” Molecular Therapy, vol. 22, May 2014, Supplement 1, p. S214. [cited by applicant]
Cong, L., et al., “Multiplex Genome Engineering Using CRISPR-Cas Systems,” Science, vol. 339, 2013, pp. 819-823. [cited by applicant]
Cong, L., et al., Supplementary Material for: “Multiplex Genome Engineering Using CRISPR-Cas Systems,” Science Express, Jul. 5, 2012, pp. 1-26. [cited by applicant]
Connor, S., “Scientific split—the human genome breakthrough dividing former colleagues,” The Independent, http://www.independent.co.uk/news/science/scientific-split--the-human-genome-breakthrough-dividing-former-colleag… [cited by applicant]
Costantino, et al., “Enhanced levels of alpha Red-mediated recombinants in mismatch repair mutants”, PNAS, vol. 100, 2003, pp. 15748-15753. [cited by applicant]
Cotropia, et al., “Copying in Patent Law,” N.C.L. Rev., Stanford Public Law Working Paper No. 1270160, 2009, pp. 1-46. [cited by applicant]
Cummings et al., “Fourteen and counting: unraveling trinucleotide repeat diseases”, Human Molecular Genetics, vol. 9, 2000, pp. 909-916. [cited by applicant]
D.J.Burgess et al., “Topoisomerase levels determine chemotherapy response in vitro and in vivo,” Proceedings of the National Academy of Sciences, vol. 105, Jul. 1, 2008, pp. 9053-9058. [cited by applicant]
Daboussi, F., et al., “Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases,” Nucleic Acids Research, vol. 40, 2012, pp. 6367-6379. [cited by applicant]
Dahlman, J., et al., “In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight,” Nature Nanotechnology, vol. 9, 2014, pp. 648-655. [cited by applicant]
Dai, et al. “Genes:Structures and Regulation: The Transcription Factors GATA4 and dHAND Physically Interact to Synergistically Activate Cardiac Gene Expression through a p300-dependent Mechanism”, J. Biol. Chem., vol. 2… [cited by applicant]
Daley, J., and Wilson, T., “Rejoining of DNA Double-Strand Breaks as a Function of Overhang Length,” Molecular and Cellular Biology, vol. 25, 2005, pp. 896-906. [cited by applicant]
Damian, M., and Porteus, M., “A Crisper Look at Genome Editing: RNA-guided Genome Modification,” Molecular Therapy, vol. 21, Apr. 2013, pp. 720-722. [cited by applicant]
DATABASE GenBank, “ [cited by applicant]
DATABASE GenBank: “CRISPR-associated protein, Csn1 family, [cited by applicant]
DATABASE UniPro Accession No. J7RUA5, 2012, [online] downloaded from https://www.uniprot.org/uniprol/J7RUA5 on Mar. 23, 2021 (10 pages). [cited by applicant]
DATABASE UniProt: “CRISPR-associated endonuclease Cas9: [cited by applicant]
DATABASE UniProtKB/TrEMBL [online], Accession No. QOP897, “The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences,” Subname: Full=Putative CRISPR-associated protein, Oct. 3, … [cited by applicant]
DATABASE UniProtKB/TrEMBL, Accession No. DOW2Z9, http://www.uniprot.org/uniprot/DOW2Z9.txt?version=4, dated Oct. 3, 2012, 1 page. [cited by applicant]
DATABASE UniProtKB/TrEMBL, Accession No. G1UFN3, http://www.uniprot.org/uniprot/G1UFN3.txt?version=3, dated Oct. 3, 2012, 1 page. [cited by applicant]